MedTrace Logo

COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2

NCT01639664 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2021-09-05

Study results available
· View outcomes & findings →

Summary

The study objective is to clarify whether the application of high doses CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit (ICU).

Conditions

  • Shock, Septic

Interventions

DEVICE

High doses CPFA

High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.

Sponsors & Collaborators

  • Bellco Srl Mirandola, Italy

    collaborator INDUSTRY

  • Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva

    lead OTHER

Principal Investigators

  • Sergio Livigni, MD · Ospedale San Giovanni Bosco, Torino, ITALY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-10-23
Completion
2017-10-23

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639664 on ClinicalTrials.gov